Healthcare / Medical Instruments & SuppliesSES
$0.13
+0.00 (+1.59%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-9.0M · quality 64.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$70M
P/E
N/A
•EV/EBITDA
33.2x
↑ROE
-4.7%
↓Gross Margin
16.0%
↓Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.0%
FCF CAGR
—
FCF margin
-11.5%
FCF / Net income
1.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $79.0M · net income $-4.8M · FCF $-9.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $79.0M | $79.0M | $54.4M | $52.6M | $56.2M |
| Net Income | $-4.8M | $-4.8M | $-22.0M | $-21.1M | $-28.6M |
| EBITDA | $2.3M | $2.3M | $-15.1M | $-14.6M | $-23.4M |
| EPS | — | — | -41.15 | -0.04 | -0.05 |
| Gross Margin | 16.0% | 16.0% | 12.7% | 11.3% | -5.9% |
| Operating Margin | -7.9% | -7.9% | -51.5% | -46.7% | -57.7% |
| Net Margin | -6.0% | -6.0% | -40.5% | -40.0% | -50.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.21 | 0.21 | 0.21 | 0.21 | 0.13 |
| Current Ratio | 1.83 | 1.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.0M | $-9.0M | $-1.0M | $-14.6M | $-16.3M |
| Returns | |||||
| ROE | -4.7% | -4.7% | -20.7% | -16.3% | -19.1% |
| Valuation | |||||
| EV/EBITDA | 33.19 | 33.19 | — | — | — |
| P/B | 0.69 | 0.69 | 0.71 | 0.77 | 0.67 |
| Growth & Yield | |||||
| Revenue Growth | 45.1% | 45.1% | 3.4% | -6.4% | — |
| EPS Growth | — | — | -106340.8% | 26.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-41.15 → n/d
Residual
+0.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.